Blockchain Registration Transaction Record

Neurothera & Clearmind File Patent for Novel Depression Therapy

Neurothera Labs & Clearmind Medicine file Israeli patent for MEAI+PEA depression therapy. New treatment targets 280M+ affected globally. 13 patents filed in partnership.

This development represents a potential breakthrough in treating depression, a condition affecting over 280 million people worldwide according to the World Health Organization. Current depression treatments often come with significant side effects and limited efficacy for many patients. The combination therapy of MEAI and PEA offers a novel approach that preclinical data suggests could mitigate addictive behaviors while preserving natural reward pathways, potentially providing a safer, more effective alternative. Given depression's status as a leading cause of global disability and the limited innovation in antidepressant treatments over recent decades, this patent filing signals important progress toward addressing a massive unmet medical need that impacts individuals, families, and healthcare systems worldwide.